Order Article Reprints

Kuno H, Nishioka N, Yamada T, Kunimatsu Y, Yoshimura A, Hirai S, Futamura S, Masui T, Egami M, Chihara Y, et al. The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study. Cancers. 2024; 16(17):3037. https://doi.org/10.3390/cancers16173037

Kuno, Haruka, Naoya Nishioka, Tadaaki Yamada, Yusuke Kunimatsu, Akihiro Yoshimura, Soichi Hirai, Shun Futamura, Taiki Masui, Masashi Egami, Yusuke Chihara, and et al. 2024. "The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study" Cancers 16, no. 17: 3037. https://doi.org/10.3390/cancers16173037

Kuno, H., Nishioka, N., Yamada, T., Kunimatsu, Y., Yoshimura, A., Hirai, S., Futamura, S., Masui, T., Egami, M., Chihara, Y., & Takayama, K. (2024). The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study. Cancers, 16(17), 3037. https://doi.org/10.3390/cancers16173037